Weijuan M. Kan

State Key Laboratory Of Drug Research
Shanghai, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 22 publications

Discovery of a Potent Fluorescence Polarization Probe for Identifying USP1 Allosteric Inhibitors.

Discovery of a Potent Fluorescence Polarization Probe for Identifying USP1 Allosteric Inhibitors.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: January 29, 2026

Design, synthesis, and evaluation of Menin-targeting compounds for the treatment of acute Myelocytic leukemia (AML).

Design, synthesis, and evaluation of Menin-targeting compounds for the treatment of acute Myelocytic leukemia (AML).

Journal: European journal of medicinal chemistry

Published: April 11, 2025

Rational engineering of degradation tail-driven CELMoD-antibody conjugates for precision malignancy therapy.

Rational engineering of degradation tail-driven CELMoD-antibody conjugates for precision malignancy therapy.

Journal: Acta pharmaceutica Sinica. B

Published: February 14, 2025

GLS1-RNA Polymerase II Axis Mediates Glutamine-Dependent Hepatoprotective Effects on Alcoholic Liver Disease in High-Protein Diets.

GLS1-RNA Polymerase II Axis Mediates Glutamine-Dependent Hepatoprotective Effects on Alcoholic Liver Disease in High-Protein Diets.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: February 12, 2025

Potent and selective LSD1 inhibitor DC551040 reveals a promising combination therapy for AML with insight into epigenetic dysregulation.

Potent and selective LSD1 inhibitor DC551040 reveals a promising combination therapy for AML with insight into epigenetic dysregulation.

Journal: Signal transduction and targeted therapy

Published: December 24, 2024

Discovery of Novel 2-Aminopyridine-Based and 2-Aminopyrimidine-Based Derivatives as Potent CDK/HDAC Dual Inhibitors for the Treatment of Refractory Solid Tumors and Hematological Malignancies.

Discovery of Novel 2-Aminopyridine-Based and 2-Aminopyrimidine-Based Derivatives as Potent CDK/HDAC Dual Inhibitors for the Treatment of Refractory Solid Tumors and Hematological Malignancies.

Journal: Journal of medicinal chemistry

Published: August 23, 2024

Design and development of a series of 4-(piperazin-1-yl)pyrimidines as irreversible menin inhibitors.

Design and development of a series of 4-(piperazin-1-yl)pyrimidines as irreversible menin inhibitors.

Journal: European journal of medicinal chemistry

Published: August 19, 2024

Discovery of a Highly Potent, Selective and Efficacious USP7 Degrader for the Treatment of Acute Lymphoblastic Leukemia.

Discovery of a Highly Potent, Selective and Efficacious USP7 Degrader for the Treatment of Acute Lymphoblastic Leukemia.

Journal: Journal of medicinal chemistry

Published: July 19, 2024

Exploratory research on the effective chemical basis of tanreqing injection for treating acute lung injury: In vivo, in vitro and in silico.

Exploratory research on the effective chemical basis of tanreqing injection for treating acute lung injury: In vivo, in vitro and in silico.

Journal: Journal of ethnopharmacology

Published: June 18, 2024

Targeted Near-Infrared Fluorescence Imaging of Liver Cancer using Dual-Peptide-Functionalized Albumin Particles.

Targeted Near-Infrared Fluorescence Imaging of Liver Cancer using Dual-Peptide-Functionalized Albumin Particles.

Journal: Chemical & biomedical imaging

Published: July 04, 2023

Discovery of Novel N-(5-(Pyridin-3-yl)-1H-indazol-3-yl)benzamide Derivatives as Potent Cyclin-Dependent Kinase 7 Inhibitors for the Treatment of Autosomal Dominant Polycystic Kidney Disease.

Discovery of Novel N-(5-(Pyridin-3-yl)-1H-indazol-3-yl)benzamide Derivatives as Potent Cyclin-Dependent Kinase 7 Inhibitors for the Treatment of Autosomal Dominant Polycystic Kidney Disease.

Journal: Journal of medicinal chemistry

Published: November 17, 2022

Structural Feature Analyzation Strategies toward Discovery of Orally Bioavailable PROTACs of Bruton's Tyrosine Kinase for the Treatment of Lymphoma.

Structural Feature Analyzation Strategies toward Discovery of Orally Bioavailable PROTACs of Bruton's Tyrosine Kinase for the Treatment of Lymphoma.

Journal: Journal of medicinal chemistry

Published: June 07, 2022

Showing 1-12 of 22

Last Updated: 09/26/2026